Carrel name: keyword-plasma-cord Creating study carrel named keyword-plasma-cord Initializing database file: cache/cord-010328-uxpedpz8.json key: cord-010328-uxpedpz8 authors: Ciencewicki, Jonathan M.; Schouest, Katherine R.; Gierman, Todd M.; Vandeberg, Peter J.; Gooch, Barry D. title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products date: 2020-04-22 journal: Sci Rep DOI: 10.1038/s41598-020-63794-y sha: doc_id: 10328 cord_uid: uxpedpz8 file: cache/cord-006192-bqwchhwk.json key: cord-006192-bqwchhwk authors: Persson, Carl G. A. title: Plasma exudation and asthma date: 1988 journal: Lung DOI: 10.1007/bf02714025 sha: doc_id: 6192 cord_uid: bqwchhwk file: cache/cord-018845-r88bhiac.json key: cord-018845-r88bhiac authors: Sachs, U. J. H.; Bux, J. title: Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten date: 2010-11-21 journal: Transfusionsmedizin und Immunhämatologie DOI: 10.1007/978-3-642-12765-6_16 sha: doc_id: 18845 cord_uid: r88bhiac file: cache/cord-018142-xt71w4nr.json key: cord-018142-xt71w4nr authors: Samy Modeliar, S.; Monge, M.; Slama, M. title: Thrombotic Microangiopathy Syndrome in the ICU date: 2006 journal: Yearbook of Intensive Care and Emergency Medicine DOI: 10.1007/3-540-33396-7_20 sha: doc_id: 18142 cord_uid: xt71w4nr file: cache/cord-270908-9snyt2n1.json key: cord-270908-9snyt2n1 authors: PERSSON, C. G. A.; ANDERSSON, M.; GREIFF, L.; SVENSSON, C.; ERJEFÄLT, J. S.; SUNDLER, F.; WOLLMER, P.; ALKNER, U.; ERJEFÄLT, I.; GUSTAFSSON, B.; LINDEN, M.; NILSSON, M. title: Airway permeability date: 2006-04-27 journal: Clin Exp Allergy DOI: 10.1111/j.1365-2222.1995.tb00022.x sha: doc_id: 270908 cord_uid: 9snyt2n1 file: cache/cord-262776-6k7tcgfs.json key: cord-262776-6k7tcgfs authors: Burnouf, Thierry; Griffiths, Elwyn; Padilla, Ana; Seddik, Salwa; Stephano, Marco Antonio; Gutiérrez, José-María title: Assessment of the viral safety of antivenoms fractionated from equine plasma date: 2004-09-30 journal: Biologicals DOI: 10.1016/j.biologicals.2004.07.001 sha: doc_id: 262776 cord_uid: 6k7tcgfs file: cache/cord-261653-0vtghtp7.json key: cord-261653-0vtghtp7 authors: Andersen, Kylie J.; Klassen, Stephen A.; Larson, Kathryn F.; Ripoll, Juan G.; Senefeld, Jonathon W.; Clayburn, Andrew J.; Shepherd, John R.A.; Tseng, Andrew S.; Wiggins, Chad C.; Johnson, Christopher P.; Miller, Andrew D.; Baker, Sarah E.; Wright, R. Scott; Winters, Jeffrey L.; Stubbs, James R.; Joyner, Michael J.; van Buskirk, Camille M. title: Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors date: 2020-09-21 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.09.021 sha: doc_id: 261653 cord_uid: 0vtghtp7 file: cache/cord-280221-s6oxq772.json key: cord-280221-s6oxq772 authors: Montelongo-Jauregui, Daniel; Vila, Taissa; Sultan, Ahmed S.; Jabra-Rizk, Mary Ann title: Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease date: 2020-08-12 journal: PLoS Pathog DOI: 10.1371/journal.ppat.1008735 sha: doc_id: 280221 cord_uid: s6oxq772 file: cache/cord-274150-ukdha3ap.json key: cord-274150-ukdha3ap authors: Choi, Jun Yong title: Convalescent Plasma Therapy for Coronavirus Disease 2019 date: 2020-09-03 journal: Infect Chemother DOI: 10.3947/ic.2020.52.3.307 sha: doc_id: 274150 cord_uid: ukdha3ap file: cache/cord-305074-wz17u4e7.json key: cord-305074-wz17u4e7 authors: Fernandez, Javier; Gratacos-Ginès, Jordi; Olivas, Pol; Costa, Montserrat; Nieto, Susana; Mateo, Dolors; Sánchez, María Belén; Aguilar, Ferran; Bassegoda, Octavi; Ruiz, Pablo; Caballol, Berta; Pocurull, Anna; Llach, Joan; Mustieles, María Jesús; Cid, Joan; Reverter, Enric; Toapanta, Nestor David; Hernández-Tejero, María; Martínez, José Antonio; Claria, Joan; Fernández, Carlos; Mensa, José; Arroyo, Vicente; Castro, Pedro; Lozano, Miquel title: Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection date: 2020-08-24 journal: Crit Care Med DOI: 10.1097/ccm.0000000000004613 sha: doc_id: 305074 cord_uid: wz17u4e7 file: cache/cord-018492-d34tyar7.json key: cord-018492-d34tyar7 authors: Zaza, Mouayyad; Kalkwarf, Kyle J.; Holcomb, John B. title: Dried Plasma date: 2019-05-06 journal: Damage Control Resuscitation DOI: 10.1007/978-3-030-20820-2_8 sha: doc_id: 18492 cord_uid: d34tyar7 file: cache/cord-329228-yjvw2ee1.json key: cord-329228-yjvw2ee1 authors: Shikata, N.; Maki, Y.; Noguchi, Y.; Mori, M.; Hanai, T.; Takahashi, M.; Okamoto, M. title: Multi-layered network structure of amino acid (AA) metabolism characterized by each essential AA-deficient condition date: 2006-10-13 journal: Amino Acids DOI: 10.1007/s00726-006-0412-0 sha: doc_id: 329228 cord_uid: yjvw2ee1 file: cache/cord-335316-x2t5h5gu.json key: cord-335316-x2t5h5gu authors: Madariaga, M. L. L.; Guthmiller, J.; Schrantz, S.; Jansen, M.; Christenson, C.; Kumar, M.; Prochaska, M.; Wool, G.; Durkin, A.; Oh, W. H.; Trockman, L.; Vigneswaran, J.; Keskey, R.; Shaw, D. G.; Dugan, H.; Zheng, N.; Cobb, M.; Utset, H.; Wang, J.; Stovicek, O.; Bethel, C.; Matushek, S.; Giurcanu, M.; Beavis, K.; diSabato, D.; Meltzer, D.; Ferguson, M.; Kress, J. P.; Shanmugarajah, K.; Matthews, J.; Fung, J.; Wilson, P.; Alverdy, J. C.; Donington, J. title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date: 2020-06-23 journal: nan DOI: 10.1101/2020.06.21.20132944 sha: doc_id: 335316 cord_uid: x2t5h5gu file: cache/cord-324908-ptlpsnfo.json key: cord-324908-ptlpsnfo authors: Cao, Huiling; Shi, Yuan title: Convalescent plasma: possible therapy for novel coronavirus disease 2019 date: 2020-05-02 journal: Transfusion DOI: 10.1111/trf.15797 sha: doc_id: 324908 cord_uid: ptlpsnfo file: cache/cord-294684-wfsdjs1f.json key: cord-294684-wfsdjs1f authors: Vesnaver, Elisabeth; Goldman, Mindy; O’Brien, Sheila; MacPherson, Paul; Butler-Foster, Terrie; Lapierre, Don; Otis, Joanne; Devine, Dana V.; Germain, Marc; Rosser, Andrew; MacDonagh, Richard; Randall, Taylor; Osbourne-Sorrell, William; Clement-Thorne, Broderic; Al-Bakri, Taim Bilal; Rubini, Kyle A.; Hill, Nolan E.; Presseau, Justin title: Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study date: 2020-11-02 journal: Health Res Policy Syst DOI: 10.1186/s12961-020-00643-4 sha: doc_id: 294684 cord_uid: wfsdjs1f file: cache/cord-271764-um001ffd.json key: cord-271764-um001ffd authors: Garraud, Olivier title: Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials? date: 2020-06-27 journal: Transfus Apher Sci DOI: 10.1016/j.transci.2020.102858 sha: doc_id: 271764 cord_uid: um001ffd file: cache/cord-284208-8fsqgkw5.json key: cord-284208-8fsqgkw5 authors: Zolla, Lello title: Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins date: 2008-11-07 journal: Drug Discov Today DOI: 10.1016/j.drudis.2008.09.013 sha: doc_id: 284208 cord_uid: 8fsqgkw5 file: cache/cord-266147-s8rxzm0t.json key: cord-266147-s8rxzm0t authors: Burnouf, Thierry title: Modern Plasma Fractionation date: 2007-03-28 journal: Transfus Med Rev DOI: 10.1016/j.tmrv.2006.11.001 sha: doc_id: 266147 cord_uid: s8rxzm0t file: cache/cord-277811-j58qvyum.json key: cord-277811-j58qvyum authors: Mehrani, Hossein; Ghanei, Mostafa; Aslani, Jafar; Tabatabaei, Zahra title: Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis date: 2011-01-07 journal: Clin Proteomics DOI: 10.1186/1559-0275-8-2 sha: doc_id: 277811 cord_uid: j58qvyum file: cache/cord-352985-5ccrkfsa.json key: cord-352985-5ccrkfsa authors: Putter, Jeffrey S.; Seghatchian, Jerard title: An Update on COVID-19 Infection Control Measures, Plasma-Based Therapeutics, Corticosteroid Pharmacotherapy and Vaccine Research date: 2020-09-04 journal: Transfus Apher Sci DOI: 10.1016/j.transci.2020.102934 sha: doc_id: 352985 cord_uid: 5ccrkfsa file: cache/cord-304616-k92fa15l.json key: cord-304616-k92fa15l authors: Izes, Aaron M.; Kimble, Benjamin; Norris, Jacqueline M.; Govendir, Merran title: Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats date: 2020-08-05 journal: PLoS One DOI: 10.1371/journal.pone.0236754 sha: doc_id: 304616 cord_uid: k92fa15l file: cache/cord-282252-07uzz649.json key: cord-282252-07uzz649 authors: Sahu, Kamal Kant; Jindal, Vishal; Siddiqui, Ahmad Daniyal; Cerny, Jan; Gerber, Jonathan M. title: Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19 date: 2020-05-21 journal: J Med Virol DOI: 10.1002/jmv.26047 sha: doc_id: 282252 cord_uid: 07uzz649 file: cache/cord-323656-bzefn894.json key: cord-323656-bzefn894 authors: Yoo, Jin-Hong title: Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying date: 2020-04-06 journal: J Korean Med Sci DOI: 10.3346/jkms.2020.35.e150 sha: doc_id: 323656 cord_uid: bzefn894 file: cache/cord-336177-p7b7yw28.json key: cord-336177-p7b7yw28 authors: Selvi, Valeria title: Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives date: 2020-09-22 journal: Biomed Res Int DOI: 10.1155/2020/2606058 sha: doc_id: 336177 cord_uid: p7b7yw28 file: cache/cord-305130-vz72ldbo.json key: cord-305130-vz72ldbo authors: Keil, Shawn D.; Ragan, Izabela; Yonemura, Susan; Hartson, Lindsay; Dart, Nicole K.; Bowen, Richard title: Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment date: 2020-05-14 journal: Vox Sang DOI: 10.1111/vox.12937 sha: doc_id: 305130 cord_uid: vz72ldbo file: cache/cord-322714-s0wge7o4.json key: cord-322714-s0wge7o4 authors: Joyner, Michael J.; Bruno, Katelyn A.; Klassen, Stephen A.; Kunze, Katie L.; Johnson, Patrick W.; Lesser, Elizabeth R.; Wiggins, Chad C.; Senefeld, Jonathon W.; Klompas, Allan M.; Hodge, David O.; Shepherd, John R.A.; Rea, Robert F.; Whelan, Emily R.; Clayburn, Andrew J.; Spiegel, Matthew R.; Baker, Sarah E.; Larson, Kathryn F.; Ripoll, Juan G.; Andersen, Kylie J.; Buras, Matthew R.; Vogt, Matthew N.P.; Herasevich, Vitaly; Dennis, Joshua J.; Regimbal, Riley J.; Bauer, Philippe R.; Blair, Janis E.; Van Buskirk, Camille M.; Winters, Jeffrey L.; Stubbs, James R.; van Helmond, Noud; Butterfield, Brian P.; Sexton, Matthew A.; Diaz Soto, Juan C.; Paneth, Nigel S.; Verdun, Nicole C.; Marks, Peter; Casadevall, Arturo; Fairweather, DeLisa; Carter, Rickey E.; Wright, R. Scott title: Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients date: 2020-07-19 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.06.028 sha: doc_id: 322714 cord_uid: s0wge7o4 file: cache/cord-284582-xwedgllw.json key: cord-284582-xwedgllw authors: Korabecna, M.; Zinkova, A.; Brynychova, I.; Chylikova, B.; Prikryl, P.; Sedova, L.; Neuzil, P.; Seda, O. title: Cell-free DNA in plasma as an essential immune system regulator date: 2020-10-15 journal: Sci Rep DOI: 10.1038/s41598-020-74288-2 sha: doc_id: 284582 cord_uid: xwedgllw file: cache/cord-328352-l1q4uvxl.json key: cord-328352-l1q4uvxl authors: Borlongan, Mia C.; Borlongan, Maximillian C.; Sanberg, Paul R. title: The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy date: 2020-08-25 journal: Cell Transplant DOI: 10.1177/0963689720940719 sha: doc_id: 328352 cord_uid: l1q4uvxl file: cache/cord-326176-n0xo3e53.json key: cord-326176-n0xo3e53 authors: Patel, Reema T.; Caceres, Ana; French, Adrienne F.; McManus, Patricia M. title: Multiple myeloma in 16 cats: a retrospective study date: 2008-03-05 journal: Vet Clin Pathol DOI: 10.1111/j.1939-165x.2005.tb00059.x sha: doc_id: 326176 cord_uid: n0xo3e53 file: cache/cord-349031-tbof9yqi.json key: cord-349031-tbof9yqi authors: Chen, Shiu-Jau; Wang, Shao-Cheng; Chen, Yuan-Chuan title: Novel Antiviral Strategies in the Treatment of COVID-19: A Review date: 2020-08-20 journal: Microorganisms DOI: 10.3390/microorganisms8091259 sha: doc_id: 349031 cord_uid: tbof9yqi file: cache/cord-294585-dl5v9p50.json key: cord-294585-dl5v9p50 authors: Klein, H. G.; Bryant, B. J. title: Pathogen‐reduction methods: advantages and limits date: 2009-02-13 journal: ISBT Sci Ser DOI: 10.1111/j.1751-2824.2009.01224.x sha: doc_id: 294585 cord_uid: dl5v9p50 file: cache/cord-351328-ly72scru.json key: cord-351328-ly72scru authors: Epstein, Jay; Burnouf, Thierry title: Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma date: 2020-05-14 journal: Vox Sang DOI: 10.1111/vox.12939 sha: doc_id: 351328 cord_uid: ly72scru file: cache/cord-319013-oytqcifa.json key: cord-319013-oytqcifa authors: Focosi, Daniele; Anderson, Arthur O.; Tang, Julian W.; Tuccori, Marco title: Convalescent Plasma Therapy for COVID-19: State of the Art date: 2020-08-12 journal: Clin Microbiol Rev DOI: 10.1128/cmr.00072-20 sha: doc_id: 319013 cord_uid: oytqcifa file: cache/cord-321697-yua3apfi.json key: cord-321697-yua3apfi authors: Crigna, Adriana Torres; Samec, Marek; Koklesova, Lenka; Liskova, Alena; Giordano, Frank A.; Kubatka, Peter; Golubnitschaja, Olga title: Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? date: 2020-10-29 journal: EPMA J DOI: 10.1007/s13167-020-00226-x sha: doc_id: 321697 cord_uid: yua3apfi file: cache/cord-006860-a3b8hyyr.json key: cord-006860-a3b8hyyr authors: nan title: 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) date: 1996 journal: Ann Hematol DOI: 10.1007/bf00641048 sha: doc_id: 6860 cord_uid: a3b8hyyr file: cache/cord-031907-ilhr3iu5.json key: cord-031907-ilhr3iu5 authors: nan title: ISEV2020 Abstract Book date: 2020-07-15 journal: nan DOI: 10.1080/20013078.2020.1784511 sha: doc_id: 31907 cord_uid: ilhr3iu5 Reading metadata file and updating bibliogrpahics === updating bibliographic database Building study carrel named keyword-plasma-cord === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 29863 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30289 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30556 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 29776 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30291 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30745 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30870 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31275 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30865 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31694 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 30991 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31362 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31520 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 29847 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31807 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 32070 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31366 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31526 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31661 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31601 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 32096 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31469 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 33834 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 33522 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 32775 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === OMP: Error #34: System unable to allocate necessary resources for OMP thread: OMP: System error #11: Resource temporarily unavailable OMP: Hint Try decreasing the value of OMP_NUM_THREADS. /data-disk/reader-compute/reader-cord/bin/file2bib.sh: line 39: 31381 Aborted $FILE2BIB "$FILE" > "$OUTPUT" === file2bib.sh === id: cord-261653-0vtghtp7 author: Andersen, Kylie J. title: Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors date: 2020-09-21 pages: extension: .txt txt: ./txt/cord-261653-0vtghtp7.txt cache: ./cache/cord-261653-0vtghtp7.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-261653-0vtghtp7.txt' === file2bib.sh === id: cord-274150-ukdha3ap author: Choi, Jun Yong title: Convalescent Plasma Therapy for Coronavirus Disease 2019 date: 2020-09-03 pages: extension: .txt txt: ./txt/cord-274150-ukdha3ap.txt cache: ./cache/cord-274150-ukdha3ap.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-274150-ukdha3ap.txt' === file2bib.sh === id: cord-282252-07uzz649 author: Sahu, Kamal Kant title: Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19 date: 2020-05-21 pages: extension: .txt txt: ./txt/cord-282252-07uzz649.txt cache: ./cache/cord-282252-07uzz649.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-282252-07uzz649.txt' === file2bib.sh === id: cord-010328-uxpedpz8 author: Ciencewicki, Jonathan M. title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products date: 2020-04-22 pages: extension: .txt txt: ./txt/cord-010328-uxpedpz8.txt cache: ./cache/cord-010328-uxpedpz8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010328-uxpedpz8.txt' === file2bib.sh === id: cord-324908-ptlpsnfo author: Cao, Huiling title: Convalescent plasma: possible therapy for novel coronavirus disease 2019 date: 2020-05-02 pages: extension: .txt txt: ./txt/cord-324908-ptlpsnfo.txt cache: ./cache/cord-324908-ptlpsnfo.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-324908-ptlpsnfo.txt' === file2bib.sh === id: cord-294585-dl5v9p50 author: Klein, H. G. title: Pathogen‐reduction methods: advantages and limits date: 2009-02-13 pages: extension: .txt txt: ./txt/cord-294585-dl5v9p50.txt cache: ./cache/cord-294585-dl5v9p50.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-294585-dl5v9p50.txt' === file2bib.sh === id: cord-319013-oytqcifa author: Focosi, Daniele title: Convalescent Plasma Therapy for COVID-19: State of the Art date: 2020-08-12 pages: extension: .txt txt: ./txt/cord-319013-oytqcifa.txt cache: ./cache/cord-319013-oytqcifa.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-319013-oytqcifa.txt' === file2bib.sh === id: cord-321697-yua3apfi author: Crigna, Adriana Torres title: Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? date: 2020-10-29 pages: extension: .txt txt: ./txt/cord-321697-yua3apfi.txt cache: ./cache/cord-321697-yua3apfi.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-321697-yua3apfi.txt' === file2bib.sh === id: cord-006860-a3b8hyyr author: nan title: 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) date: 1996 pages: extension: .txt txt: ./txt/cord-006860-a3b8hyyr.txt cache: ./cache/cord-006860-a3b8hyyr.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 9 resourceName b'cord-006860-a3b8hyyr.txt' === file2bib.sh === id: cord-031907-ilhr3iu5 author: nan title: ISEV2020 Abstract Book date: 2020-07-15 pages: extension: .txt txt: ./txt/cord-031907-ilhr3iu5.txt cache: ./cache/cord-031907-ilhr3iu5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 18 resourceName b'cord-031907-ilhr3iu5.txt' Que is empty; done keyword-plasma-cord === reduce.pl bib === === reduce.pl bib === id = cord-010328-uxpedpz8 author = Ciencewicki, Jonathan M. title = Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products date = 2020-04-22 pages = extension = .txt mime = text/plain words = 4560 sentences = 208 flesch = 51 summary = In this study, source plasma from donation centers in various locations of the Southwestern quarter of the United States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV). Safety measures implemented nearly two decades ago-collaborative, industry-wide epidemiological surveillance of the donor population, judicious selection of donors, rigorous testing of plasma by serological and molecular (e.g., nucleic acid testing) methods and validation of manufacturing methods for virus clearance capacity-provide a high degree of confidence that IG products, regardless of plasma origin, safely deliver a diverse, natural combination of human polyclonal antibodies 1,2 . The analyses of individual units originating from select pools served to demonstrate that a number of centers in the US Southwest are capable of consistently generating plasma with elevated anti-HAV Ig titers. cache = ./cache/cord-010328-uxpedpz8.txt txt = ./txt/cord-010328-uxpedpz8.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-261653-0vtghtp7 author = Andersen, Kylie J. title = Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors date = 2020-09-21 pages = extension = .txt mime = text/plain words = 1666 sentences = 95 flesch = 46 summary = Thus, the present narrative overviews the strategy developed by our team to identify and recruit COVID-19 survivors to donate convalescent plasma at the Mayo Clinic Blood Donor Center in Rochester, Minnesota. Rochester, Minnesota required a strategy to interface with the community of recovering COVID-19 patients and recruit eligible convalescent plasma donors. Overall, this recruitment strategy utilized a simple survey, an algorithm for triaging donors, a workflow for connecting donors with Mayo Clinic Blood Donor Center, a team of physician navigators (including medical students) to screen eligible donors, and a support center for donor questions. Our web-based recruitment survey and all e-mail communications to interested potential donors contained the e-mail address for our convalescent plasma service center. The service center team used available resources from the US FDA, Mayo Clinic, and the blood banking community to support questions regarding donor eligibility and COVID-19 testing. cache = ./cache/cord-261653-0vtghtp7.txt txt = ./txt/cord-261653-0vtghtp7.txt === reduce.pl bib === === reduce.pl bib === id = cord-274150-ukdha3ap author = Choi, Jun Yong title = Convalescent Plasma Therapy for Coronavirus Disease 2019 date = 2020-09-03 pages = extension = .txt mime = text/plain words = 3163 sentences = 169 flesch = 42 summary = Given its rapid acquisition, convalescent plasma therapy has been considered as an emergency intervention in several pandemics, including the Spanish flu, severe acute respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more recently, Ebola virus [7] [8] [9] . Although large-scale randomized controlled trials have not yet been performed, and most studies did not evaluate neutralizing activities of used convalescent plasma, previous experiences on convalescent plasma therapy for the treatment of emerging infectious diseases provide us with important historical precedents that this intervention might be useful for confronting the COVID-19 epidemics. To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID19 , an open-label, multicenter, randomized clinical trial was performed in seven medical centers in Wuhan, China. Some patients who recover from viral diseases may not have high titers of neutralizing antibodies, which are crucial for the effectiveness of convalescent plasma therapy [13, 14] . cache = ./cache/cord-274150-ukdha3ap.txt txt = ./txt/cord-274150-ukdha3ap.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-324908-ptlpsnfo author = Cao, Huiling title = Convalescent plasma: possible therapy for novel coronavirus disease 2019 date = 2020-05-02 pages = extension = .txt mime = text/plain words = 2794 sentences = 182 flesch = 53 summary = 16 Public Health of England and the International Severe Acute Respiratory and Emerging Infection Consortium 17 put forward that convalescent plasma could be a promising specific treatment for serious Middle East respiratory syndrome (MERS), and further evaluation is needed in human clinical trials. Although many studies have reported the efficacy and safety of convalescent plasma infusion in the treatment of various infections, due to the lack of large-scale, randomized, well-designed, and prospective clinical trials, we tend to consider convalescent plasma as an "empirical" therapy. Mortality in the treatment group was significantly lower than in the nontreatment group ( controlled trial reported that patients who received immune plasma and standard care for severe influenza showed a nonsignificant reduction in the mortality rate. In conclusion, the transfusion of up to 500 mL of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed Ebola virus infection was not associated with a significant improvement in survival. cache = ./cache/cord-324908-ptlpsnfo.txt txt = ./txt/cord-324908-ptlpsnfo.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-282252-07uzz649 author = Sahu, Kamal Kant title = Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19 date = 2020-05-21 pages = extension = .txt mime = text/plain words = 1366 sentences = 94 flesch = 55 summary = The basic concept for use of convalescent plasma in COVID-19 is as a delivery system for viral neutralizing antibodies, that is to confer passive immunity. Considering the aforementioned limitations and the potential risks, appropriate triage systems should be utilized; hence, plasma therapy use is currently restricted only to critically ill patients. The FDA recommends two clinical indications for the current usage of convalescent plasma therapy in COVID-19 patients(12) Scenario A (Severe disease) which is defined as one or more of the following: On April 3, 2020, the FDA cleared the path for the use of this potential lifesaving therapy under any of the following three routes[1] enrollment in a clinical trial, [2] via the national expanded access treatment protocol, and [3] under a single patient emergency investigational new drug application (eIND). Lacking a vaccine and with limited antiviral options against SARS-CoV-2, this is an ideal time to try convalescent plasma therapy in COVID-19 patients. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients cache = ./cache/cord-282252-07uzz649.txt txt = ./txt/cord-282252-07uzz649.txt === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === === reduce.pl bib === id = cord-294585-dl5v9p50 author = Klein, H. G. title = Pathogen‐reduction methods: advantages and limits date = 2009-02-13 pages = extension = .txt mime = text/plain words = 4519 sentences = 216 flesch = 40 summary = However, because blood contains numerous labile proteins and fragile cells, and because there is a wide array of potentially infectious agents, no single method of pathogen-inactivation will likely preserve all blood components, yet effectively remove all viruses, bacteria, spores, protozoa and prions. Riboflavin/ultraviolet light treatment has been evaluated in preclinical studies and found to result in reduction of infectivity by many pathogens including west Nile virus, intracellular HIV, bacteria and protozoa. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients cache = ./cache/cord-294585-dl5v9p50.txt txt = ./txt/cord-294585-dl5v9p50.txt === reduce.pl bib === id = cord-319013-oytqcifa author = Focosi, Daniele title = Convalescent Plasma Therapy for COVID-19: State of the Art date = 2020-08-12 pages = extension = .txt mime = text/plain words = 7474 sentences = 335 flesch = 41 summary = In the first retrospective, randomized controlled trial published to date, 39 patients in New York with severe COVID-19 were transfused with 2 units of ABO-type matched CP with anti-Spike antibody titers of Ն1:320 (measured by a two-step Spike proteindirected ELISA). CP (9 to 13 ml/kg from donors with S-RBD IgG titer of Ն1:640) was associated with a negative SARS-CoV-2 PCR test at 72 h in 87.2% of the CP group versus 37.5% of the BSC group, but clinical improvement at 28 days was statistically different only in patients with severe, but not in life-threatening, disease (104) . Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 cache = ./cache/cord-319013-oytqcifa.txt txt = ./txt/cord-319013-oytqcifa.txt === reduce.pl bib === === reduce.pl bib === id = cord-321697-yua3apfi author = Crigna, Adriana Torres title = Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? date = 2020-10-29 pages = extension = .txt mime = text/plain words = 10892 sentences = 608 flesch = 40 summary = This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Especially severe, prolonged and/ or chronic stress of any origin such as exercise-induced oxidative stress [22] (see "Physical activity and exercise-induced oxidative stress" section), hormonal stress [23] , emotional stress and psychological burden [24] [25] [26] [27] as well as metabolic stress, e.g. in diabetes mellitus [28, 29] (see also below "Association between diabetes mellitus and carcinogenesis: diagnostic and therapeutic potential of cell-free nucleic acids" section) and hyperhomocysteinaemia [30, 31] amongst others, is associated with highly increased ROS production and insufficient repair capacity-both linked to oxidative damage of mitochondria and consequent mitochondrial dysfunction leading to the development of cardiovascular impairments [32] [33] [34] , neuro/degenerative pathologies [34] [35] [36] [37] , impaired healing [34] and malignant cell transformation [34, [38] [39] [40] [41] [42] . cache = ./cache/cord-321697-yua3apfi.txt txt = ./txt/cord-321697-yua3apfi.txt === reduce.pl bib === === reduce.pl bib === id = cord-006860-a3b8hyyr author = nan title = 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) date = 1996 pages = extension = .txt mime = text/plain words = 90660 sentences = 5152 flesch = 50 summary = Dept of Pediatrics, University Hospitals Kiel and Mtinster, Germany Resistance to activated protein C (APCR), in the majority of cases associated with the Arg 506 Gin point mutation in the factor V gene is present in more than 50 % of patients < 60 years of age with unexplained thrombophilia. The regular APC resistance test is not applicable to plasma from Orally anticoagulated (OAC) or heparinized patients due to decreased levels of vitamin K-dependent clotting factors and to thrombin inhibition by antithrombin, respectively. On admission an extensive coagulation screen yielded the following results (n/normal, t/elevated, I/reduced, +/positive, -/negative): PT t, aPTT t, Tr n, factor II, V, VIII n, factor VII, IX, XI, XII /,, fibrinogan t, ATIII n, protein C, S *, activated protein C sensitivity ratio 1.92 ($), FV-Leidenmutation PCR -, fibrinolytic system n, TAT t, Ft÷2 t, lupus anticoagulant +, heparin induced platelet antibodies +; no diagnosis of a specific autoimmuna disorder could be made. cache = ./cache/cord-006860-a3b8hyyr.txt txt = ./txt/cord-006860-a3b8hyyr.txt === reduce.pl bib === id = cord-031907-ilhr3iu5 author = nan title = ISEV2020 Abstract Book date = 2020-07-15 pages = extension = .txt mime = text/plain words = 200999 sentences = 11528 flesch = 44 summary = L.M., and the National Institutes of Health (R35GM119623) to T.R.G. The addition of a size exclusion chromatography step to various urinary extracellular vesicle concentrating methods reveals differences in the small RNA profile Introduction: Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases, however non-vesicular RNA (e.g. associated with proteins) is also present within urine. We then evaluated efficiency of heart targeting for eAAV9 or eAAV6 and standard AAV9 or AAV6 encoding for EGFP, mCherry or firefly luciferase in different human cell lines in vitro, in black mouse and in passive immunity nude mouse model in vivo using flow cytometry, confocal microscopy, Langendorff perfusion system and Methods: HLHS patients (n = 3) after Glenn procedure and swine (n = 3) after PAB were given RV injections of allogeneic/xenogeneic MSCs. Donor-specific, HLA-I+, exosomes were isolated from plasma. cache = ./cache/cord-031907-ilhr3iu5.txt txt = ./txt/cord-031907-ilhr3iu5.txt ===== Reducing email addresses cord-305074-wz17u4e7 cord-329228-yjvw2ee1 Creating transaction Updating adr table ===== Reducing keywords cord-010328-uxpedpz8 cord-018845-r88bhiac cord-006192-bqwchhwk cord-018142-xt71w4nr cord-270908-9snyt2n1 cord-262776-6k7tcgfs cord-261653-0vtghtp7 cord-274150-ukdha3ap cord-280221-s6oxq772 cord-018492-d34tyar7 cord-305074-wz17u4e7 cord-329228-yjvw2ee1 cord-335316-x2t5h5gu cord-294684-wfsdjs1f cord-324908-ptlpsnfo cord-271764-um001ffd cord-284208-8fsqgkw5 cord-277811-j58qvyum cord-266147-s8rxzm0t cord-352985-5ccrkfsa cord-304616-k92fa15l cord-282252-07uzz649 cord-323656-bzefn894 cord-336177-p7b7yw28 cord-305130-vz72ldbo cord-322714-s0wge7o4 cord-284582-xwedgllw cord-328352-l1q4uvxl cord-326176-n0xo3e53 cord-349031-tbof9yqi cord-351328-ly72scru cord-321697-yua3apfi cord-319013-oytqcifa cord-006860-a3b8hyyr cord-031907-ilhr3iu5 cord-294585-dl5v9p50 Creating transaction Updating wrd table ===== Reducing urls cord-010328-uxpedpz8 cord-261653-0vtghtp7 cord-305074-wz17u4e7 cord-335316-x2t5h5gu cord-324908-ptlpsnfo cord-284208-8fsqgkw5 cord-277811-j58qvyum cord-304616-k92fa15l cord-321697-yua3apfi cord-284582-xwedgllw cord-031907-ilhr3iu5 cord-328352-l1q4uvxl cord-319013-oytqcifa Creating transaction Updating url table ===== Reducing named entities cord-010328-uxpedpz8 cord-006192-bqwchhwk cord-018142-xt71w4nr cord-270908-9snyt2n1 cord-261653-0vtghtp7 cord-262776-6k7tcgfs cord-280221-s6oxq772 cord-018845-r88bhiac cord-274150-ukdha3ap cord-305074-wz17u4e7 cord-018492-d34tyar7 cord-329228-yjvw2ee1 cord-335316-x2t5h5gu cord-324908-ptlpsnfo cord-294684-wfsdjs1f cord-271764-um001ffd cord-284208-8fsqgkw5 cord-266147-s8rxzm0t cord-277811-j58qvyum cord-352985-5ccrkfsa cord-304616-k92fa15l cord-323656-bzefn894 cord-282252-07uzz649 cord-336177-p7b7yw28 cord-305130-vz72ldbo cord-322714-s0wge7o4 cord-284582-xwedgllw cord-328352-l1q4uvxl cord-326176-n0xo3e53 cord-349031-tbof9yqi cord-294585-dl5v9p50 cord-351328-ly72scru cord-319013-oytqcifa cord-321697-yua3apfi cord-006860-a3b8hyyr cord-031907-ilhr3iu5 Creating transaction Updating ent table ===== Reducing parts of speech cord-010328-uxpedpz8 cord-261653-0vtghtp7 cord-280221-s6oxq772 cord-018142-xt71w4nr cord-006192-bqwchhwk cord-270908-9snyt2n1 cord-274150-ukdha3ap cord-305074-wz17u4e7 cord-018845-r88bhiac cord-329228-yjvw2ee1 cord-335316-x2t5h5gu cord-262776-6k7tcgfs cord-018492-d34tyar7 cord-324908-ptlpsnfo cord-271764-um001ffd cord-277811-j58qvyum cord-352985-5ccrkfsa cord-294684-wfsdjs1f cord-284208-8fsqgkw5 cord-304616-k92fa15l cord-336177-p7b7yw28 cord-323656-bzefn894 cord-305130-vz72ldbo cord-282252-07uzz649 cord-328352-l1q4uvxl cord-322714-s0wge7o4 cord-351328-ly72scru cord-266147-s8rxzm0t cord-284582-xwedgllw cord-349031-tbof9yqi cord-294585-dl5v9p50 cord-326176-n0xo3e53 cord-319013-oytqcifa cord-321697-yua3apfi cord-006860-a3b8hyyr cord-031907-ilhr3iu5 Creating transaction Updating pos table Building ./etc/reader.txt cord-031907-ilhr3iu5 cord-018492-d34tyar7 cord-319013-oytqcifa cord-031907-ilhr3iu5 cord-319013-oytqcifa cord-336177-p7b7yw28 number of items: 36 sum of words: 328,093 average size in words: 32,809 average readability score: 46 nouns: plasma; evs; cells; patients; cell; blood; results; protein; ev; methods; treatment; cancer; analysis; study; proteins; vesicles; disease; conclusion; expression; therapy; samples; levels; exosomes; factor; time; platelet; introduction; studies; data; size; activity; markers; virus; activation; use; effects; serum; tumour; method; effect; role; system; concentration; ml; surface; risk; detection; assay; antibodies; group verbs: used; shown; derived; increased; compare; isolated; associated; including; induce; found; identified; treated; demonstrate; based; perform; developed; followed; determine; provide; detected; suggested; reducing; measured; containing; observed; obtained; characterized; dying; reported; investigate; evaluated; revealed; analysed; resulting; expressed; circulating; assessed; relate; binding; confirm; causing; produce; indicated; leading; required; known; collected; released; allow; decreasing adjectives: human; convalescent; extracellular; clinical; high; different; specific; therapeutic; anti; small; severe; viral; normal; low; non; higher; significant; potential; immune; acute; new; molecular; inflammatory; several; healthy; novel; first; early; free; single; important; multiple; endothelial; large; cellular; present; total; positive; respiratory; western; whole; available; various; many; effective; functional; dependent; similar; biological; major adverbs: also; however; well; significantly; therefore; respectively; highly; furthermore; previously; recently; currently; still; moreover; even; directly; additionally; especially; potentially; often; critically; differentially; prior; finally; clinically; particularly; less; yet; usually; now; specifically; first; immediately; together; interestingly; widely; approximately; mainly; alone; rapidly; largely; hence; rather; probably; successfully; strongly; relatively; typically; similarly; generally; far pronouns: we; their; it; our; its; they; i; them; us; he; his; itself; themselves; your; you; one; her; my; thier; she; ourselves; me; a1-antitrypsin; und; sevs; ofvwd; nsp(+)-evs; myself; mrnas; mir-1202; mine; microev; mg; j824; i.v.-gabe; him; exrna; egfp; ccrcc; casp3-/mice; casp3-/-mice; aptt; + proper nouns: EV; Summary; RNA; COVID-19; der; EVs; MSC; SARS; miRNA; University; C; NTA; miRNAs; von; USA; APC; Extracellular; CD63; CoV-2; MS; SEC; CD9; exosomes; PCR; mg; werden; Plasma; ELISA; VIII; PA; S; Introduction; HIV; F; CD81; TEM; und; National; Exosomes; T; A; II; Health; DNA; Research; Institute; Convalescent; IgG; US; UC keywords: plasma; covid-19; protein; patient; convalescent; cell; sars; dna; study; blood; virus; viral; rna; result; pcr; msc; increase; high; elisa; crc; cancer; airway; western; werden; von; viii; vesicle; usa; university; und; ttp; treatment; tma; time; thrombozyten; tem; teg; tau; summary; sta; spender; spanish; size; sec; sample; research; regel; rbd; proteomic; product one topic; one dimension: plasma file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176631/ titles(s): Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products three topics; one dimension: evs; plasma; der file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480431/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103196/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123830/ titles(s): ISEV2020 Abstract Book | 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) | Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten five topics; three dimensions: evs ev cells; plasma convalescent patients; patients factor blood; der die mir; amino plasma gbmsm file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480431/, https://www.sciencedirect.com/science/article/pii/S1045105604000223, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103196/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123830/, https://www.ncbi.nlm.nih.gov/pubmed/33138828/ titles(s): ISEV2020 Abstract Book | Assessment of the viral safety of antivenoms fractionated from equine plasma | 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) | Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten | Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study Type: cord title: keyword-plasma-cord date: 2021-05-25 time: 16:06 username: emorgan patron: Eric Morgan email: emorgan@nd.edu input: keywords:plasma ==== make-pages.sh htm files ==== make-pages.sh complex files ==== make-pages.sh named enities ==== making bibliographics id: cord-261653-0vtghtp7 author: Andersen, Kylie J. title: Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors date: 2020-09-21 words: 1666.0 sentences: 95.0 pages: flesch: 46.0 cache: ./cache/cord-261653-0vtghtp7.txt txt: ./txt/cord-261653-0vtghtp7.txt summary: Thus, the present narrative overviews the strategy developed by our team to identify and recruit COVID-19 survivors to donate convalescent plasma at the Mayo Clinic Blood Donor Center in Rochester, Minnesota. Rochester, Minnesota required a strategy to interface with the community of recovering COVID-19 patients and recruit eligible convalescent plasma donors. Overall, this recruitment strategy utilized a simple survey, an algorithm for triaging donors, a workflow for connecting donors with Mayo Clinic Blood Donor Center, a team of physician navigators (including medical students) to screen eligible donors, and a support center for donor questions. Our web-based recruitment survey and all e-mail communications to interested potential donors contained the e-mail address for our convalescent plasma service center. The service center team used available resources from the US FDA, Mayo Clinic, and the blood banking community to support questions regarding donor eligibility and COVID-19 testing. abstract: nan url: https://api.elsevier.com/content/article/pii/S0025619620310557 doi: 10.1016/j.mayocp.2020.09.021 id: cord-328352-l1q4uvxl author: Borlongan, Mia C. title: The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy date: 2020-08-25 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Coronavirus disease 2019 or COVID-19 is highly infectious, which can lead to acute and chronic debilitating symptoms, as well as mortality. The advent of safe and effective vaccines or antiviral drugs remains distant in the future. Practical public health measures, such as social distancing, hand washing, and wearing a face mask, are the current recommended guidelines by the Centers for Disease Control and Prevention for limiting the spread of the virus. Weakened immune system and aberrant inflammation represent a major pathological symptom of COVID-19 patients. Based on the unique immunomodulatory properties of both convalescent plasma and stem cells, we discuss here their potential use for treating COVID-19. url: https://doi.org/10.1177/0963689720940719 doi: 10.1177/0963689720940719 id: cord-262776-6k7tcgfs author: Burnouf, Thierry title: Assessment of the viral safety of antivenoms fractionated from equine plasma date: 2004-09-30 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Abstract Antivenoms are preparations of intact or fragmented (F(ab′)2 or Fab) immunoglobulin G (IgG) used in human medicine to treat the severe envenomings resulting from the bites and stings of various animals, such as snakes, spiders, scorpions, or marine animals, or from the contact with poisonous plants. They are obtained by fractionating plasma collected from immunized horses or, less frequently, sheep. Manufacturing processes usually include pepsin digestion at acid pH, papain digestion, ammonium sulphate precipitation, caprylic acid precipitation, heat coagulation and/or chromatography. Most production processes do not have deliberately introduced viral inactivation or removal treatments, but antivenoms have never been found to transmit viruses to humans. Nevertheless, the recent examples of zoonotic diseases highlight the need to perform a careful assessment of the viral safety of antivenoms. This paper reviews the characteristics of equine viruses of antivenoms and discusses the potential of some manufacturing steps to avoid risks of viral contamination. Analysis of production parameters indicate that acid pH treatments and caprylic acid precipitations, which have been validated for the manufacture of some human IgG products, appear to provide the best potential for viral inactivation of antivenoms. As many manufacturers of antivenoms located in developing countries lack the resources to conduct formal viral validation studies, it is hoped that this review will help in the scientific understanding of the viral safety factors of antivenoms, in the controlled implementation of the manufacturing steps with expected impact on viral safety, and in the overall reinforcement of good manufacturing practices of these essential therapeutic products. url: https://www.sciencedirect.com/science/article/pii/S1045105604000223 doi: 10.1016/j.biologicals.2004.07.001 id: cord-266147-s8rxzm0t author: Burnouf, Thierry title: Modern Plasma Fractionation date: 2007-03-28 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Protein products fractionated from human plasma are an essential class of therapeutics used, often as the only available option, in the prevention, management, and treatment of life-threatening conditions resulting from trauma, congenital deficiencies, immunologic disorders, or infections. Modern plasma product production technology remains largely based on the ethanol fractionation process, but much has evolved in the last few years to improve product purity, to enhance the recovery of immunoglobulin G, and to isolate new plasma proteins, such as α1-protease inhibitor, von Willebrand factor, and protein C. Because of the human origin of the starting material and the pooling of 10 000 to 50 000 donations required for industrial processing, the major risk associated to plasma products is the transmission of blood-borne infectious agents. A complete set of measures—and, most particularly, the use of dedicated viral inactivation and removal treatments—has been implemented throughout the production chain of fractionated plasma products over the last 20 years to ensure optimal safety, in particular, and not exclusively, against HIV, hepatitis B virus, and hepatitis C virus. In this review, we summarize the practices of the modern plasma fractionation industry from the collection of the raw plasma material to the industrial manufacture of fractionated products. We describe the quality requirements of plasma for fractionation and the various treatments applied for the inactivation and removal of blood-borne infectious agents and provide examples of methods used for the purification of the various classes of plasma protein therapies. We also highlight aspects of the good manufacturing practices and the regulatory environment that govern the whole chain of production. In a regulated and professional environment, fractionated plasma products manufactured by modern processes are certainly among the lowest-risk therapeutic biological products in use today. url: https://www.sciencedirect.com/science/article/pii/S0887796306000940 doi: 10.1016/j.tmrv.2006.11.001 id: cord-324908-ptlpsnfo author: Cao, Huiling title: Convalescent plasma: possible therapy for novel coronavirus disease 2019 date: 2020-05-02 words: 2794.0 sentences: 182.0 pages: flesch: 53.0 cache: ./cache/cord-324908-ptlpsnfo.txt txt: ./txt/cord-324908-ptlpsnfo.txt summary: 16 Public Health of England and the International Severe Acute Respiratory and Emerging Infection Consortium 17 put forward that convalescent plasma could be a promising specific treatment for serious Middle East respiratory syndrome (MERS), and further evaluation is needed in human clinical trials. Although many studies have reported the efficacy and safety of convalescent plasma infusion in the treatment of various infections, due to the lack of large-scale, randomized, well-designed, and prospective clinical trials, we tend to consider convalescent plasma as an "empirical" therapy. Mortality in the treatment group was significantly lower than in the nontreatment group ( controlled trial reported that patients who received immune plasma and standard care for severe influenza showed a nonsignificant reduction in the mortality rate. In conclusion, the transfusion of up to 500 mL of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed Ebola virus infection was not associated with a significant improvement in survival. abstract: nan url: https://doi.org/10.1111/trf.15797 doi: 10.1111/trf.15797 id: cord-349031-tbof9yqi author: Chen, Shiu-Jau title: Novel Antiviral Strategies in the Treatment of COVID-19: A Review date: 2020-08-20 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS–CoV-2), is still a global public health problem for humans. It has caused more than 10,000,000 infections and more than 500,000 deaths in the world so far. Many scientists have tried their best to discover safe and effective drugs for the treatment of this disease; however, there are still no approved standard therapeutics or effective antiviral drugs on the market. Many new drugs are being developed, and several traditional drugs that were originally indicated or proposed for other diseases are likely to be effective in treating COVID-19, but their safety and efficacy are controversial, under study, or in clinical trial phases. Fortunately, some novel antiviral strategies, such as convalescent plasma, clustered regularly interspaced short palindromic repeats (CRISPR), and mesenchymal stem cell (MSC) therapy, potentially offer an additional or alternative option or compassionate use for the people suffering from COVID-19, especially for critically ill patients, although their safety and efficacy are also under study. In this review, we explore the applications, possible mechanisms, and efficacy in successful cases using convalescent plasma, CRISPR, and MSC therapy for COVID-19 treatment, respectively. Furthermore, the perspectives and limitations of these novel antiviral strategies are evaluated. url: https://doi.org/10.3390/microorganisms8091259 doi: 10.3390/microorganisms8091259 id: cord-274150-ukdha3ap author: Choi, Jun Yong title: Convalescent Plasma Therapy for Coronavirus Disease 2019 date: 2020-09-03 words: 3163.0 sentences: 169.0 pages: flesch: 42.0 cache: ./cache/cord-274150-ukdha3ap.txt txt: ./txt/cord-274150-ukdha3ap.txt summary: Given its rapid acquisition, convalescent plasma therapy has been considered as an emergency intervention in several pandemics, including the Spanish flu, severe acute respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more recently, Ebola virus [7] [8] [9] . Although large-scale randomized controlled trials have not yet been performed, and most studies did not evaluate neutralizing activities of used convalescent plasma, previous experiences on convalescent plasma therapy for the treatment of emerging infectious diseases provide us with important historical precedents that this intervention might be useful for confronting the COVID-19 epidemics. To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID19 , an open-label, multicenter, randomized clinical trial was performed in seven medical centers in Wuhan, China. Some patients who recover from viral diseases may not have high titers of neutralizing antibodies, which are crucial for the effectiveness of convalescent plasma therapy [13, 14] . abstract: Convalescent plasma has been used for decades to prevent and treat a wide range of infectious diseases for which no specific treatment is available. The use of convalescent plasma involves transfusing plasma collected from patients who have recovered from a viral illness, in an attempt to transfer virus-neutralizing antibodies and confer passive immunity. In addition to the antiviral mechanisms of neutralizing antibodies, the immunomodulatory effects of plasma components could have benefits. Several small and large-scale studies have shown the effects of convalescent plasma for the treatment of severe coronavirus disease 2019 (COVID-19). In addition to transfusion-related side effects, unexpected side effects such as antibody-dependent enhancement (ADE) may occur during convalescent plasma therapy, but early safety studies have not found any cases of ADE among more than 5,000 participants. With historical precedents and recent clinical studies, convalescent plasma therapy should be considered as a candidate therapy for COVID-19 given the limited effectiveness of antiviral drugs and lack of a vaccine. A system to secure safe collection and use of convalescent plasma should be developed as a response to the pandemic. Further clinical trials should be conducted to determine the safety and efficacy of convalescent plasma therapy concurrently with its clinical use. url: https://www.ncbi.nlm.nih.gov/pubmed/32989938/ doi: 10.3947/ic.2020.52.3.307 id: cord-010328-uxpedpz8 author: Ciencewicki, Jonathan M. title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products date: 2020-04-22 words: 4560.0 sentences: 208.0 pages: flesch: 51.0 cache: ./cache/cord-010328-uxpedpz8.txt txt: ./txt/cord-010328-uxpedpz8.txt summary: In this study, source plasma from donation centers in various locations of the Southwestern quarter of the United States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV). Safety measures implemented nearly two decades ago-collaborative, industry-wide epidemiological surveillance of the donor population, judicious selection of donors, rigorous testing of plasma by serological and molecular (e.g., nucleic acid testing) methods and validation of manufacturing methods for virus clearance capacity-provide a high degree of confidence that IG products, regardless of plasma origin, safely deliver a diverse, natural combination of human polyclonal antibodies 1,2 . The analyses of individual units originating from select pools served to demonstrate that a number of centers in the US Southwest are capable of consistently generating plasma with elevated anti-HAV Ig titers. abstract: Human-plasma-derived immune globulin (IG) is used in augmentation therapy to provide protective levels of antibodies to patients with primary immune deficiency diseases (PIDD) and for prophylaxis against infectious diseases. To maintain the breadth of antibodies necessary for clinical protection, it is important to understand regional patterns of antibody seroprevalence in source plasma from which IG products are manufactured. In this study, source plasma from donation centers in various locations of the Southwestern quarter of the United States was surveyed for antibody titers to hepatitis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV). A broad range of anti-HAV Ig plasma titers was observed among these centers, with some centers exhibiting 3–5 times the titers of the others. Minor to no differences were observed for levels of anti-MeV and anti-CMV, respectively. Importantly, elevated anti-HAV Ig titers were broadly observed across plasma units obtained from the centers exhibiting high titers, indicative of a potential regional phenomenon among donors as opposed to few donors with singularly high titers. Plasma from these high-titer centers conferred significantly greater neutralization against HAV in vitro. The outcomes of this study give a glimpse of the antibody diversity inherent in human plasma used to manufacture IG products.. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176631/ doi: 10.1038/s41598-020-63794-y id: cord-321697-yua3apfi author: Crigna, Adriana Torres title: Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope? date: 2020-10-29 words: 10892.0 sentences: 608.0 pages: flesch: 40.0 cache: ./cache/cord-321697-yua3apfi.txt txt: ./txt/cord-321697-yua3apfi.txt summary: This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Especially severe, prolonged and/ or chronic stress of any origin such as exercise-induced oxidative stress [22] (see "Physical activity and exercise-induced oxidative stress" section), hormonal stress [23] , emotional stress and psychological burden [24] [25] [26] [27] as well as metabolic stress, e.g. in diabetes mellitus [28, 29] (see also below "Association between diabetes mellitus and carcinogenesis: diagnostic and therapeutic potential of cell-free nucleic acids" section) and hyperhomocysteinaemia [30, 31] amongst others, is associated with highly increased ROS production and insufficient repair capacity-both linked to oxidative damage of mitochondria and consequent mitochondrial dysfunction leading to the development of cardiovascular impairments [32] [33] [34] , neuro/degenerative pathologies [34] [35] [36] [37] , impaired healing [34] and malignant cell transformation [34, [38] [39] [40] [41] [42] . abstract: Interest in the use of cell-free nucleic acids (CFNAs) as clinical non-invasive biomarker panels for prediction and prevention of multiple diseases has greatly increased over the last decade. Indeed, circulating CFNAs are attributable to many physiological and pathological processes such as imbalanced stress conditions, physical activities, extensive apoptosis of different origin, systemic hypoxic-ischemic events and tumour progression, amongst others. This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Presented considerations conform with principles of 3P medicine and serve for improving individual outcomes and cost efficacy of medical services provided to the population. url: https://doi.org/10.1007/s13167-020-00226-x doi: 10.1007/s13167-020-00226-x id: cord-351328-ly72scru author: Epstein, Jay title: Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma date: 2020-05-14 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. The document covers the following important factors to have in mind when considering this treatment: (a) eligibility criteria of convalescent COVID-19 patients to donate whole blood or plasma, (b) pre-screening and pre-donation testing of convalescent COVID-19 donors; (c) criteria for collection of COVID-19 plasma; (d) post-donation treatment of plasma; and (e) it offers recommendations for plasma transfusion. url: https://doi.org/10.1111/vox.12939 doi: 10.1111/vox.12939 id: cord-305074-wz17u4e7 author: Fernandez, Javier title: Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection date: 2020-08-24 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Infection by severe acute respiratory syndrome coronavirus-2 can induce uncontrolled systemic inflammation and multiple organ failure. The aim of this study was to evaluate if plasma exchange, through the removal of circulating mediators, can be used as rescue therapy in these patients. DESIGN: Single center case series. SETTING: Local study. SUBJECTS: Four critically ill adults with coronavirus disease 19 pneumonia that failed conventional interventions. INTERVENTIONS: Plasma exchange. Two to six sessions (1.2 plasma volumes). Human albumin (5%) was used as the main replacement fluid. Fresh frozen plasma and immunoglobulins were administered after each session to avoid coagulopathy and hypogammaglobulinemia. MEASUREMENTS AND MAIN RESULTS: Serum markers of inflammation and macrophage activation. All patients showed a dramatic reduction in inflammatory markers, including the main cytokines, and improved severity scores after plasma exchange. All survived to ICU admission. CONCLUSIONS: Plasma exchange mitigates cytokine storm, reverses organ failure, and could improve survival in critically ill patients with coronavirus disease 2019 infection. url: https://www.ncbi.nlm.nih.gov/pubmed/32833695/ doi: 10.1097/ccm.0000000000004613 id: cord-319013-oytqcifa author: Focosi, Daniele title: Convalescent Plasma Therapy for COVID-19: State of the Art date: 2020-08-12 words: 7474.0 sentences: 335.0 pages: flesch: 41.0 cache: ./cache/cord-319013-oytqcifa.txt txt: ./txt/cord-319013-oytqcifa.txt summary: In the first retrospective, randomized controlled trial published to date, 39 patients in New York with severe COVID-19 were transfused with 2 units of ABO-type matched CP with anti-Spike antibody titers of Ն1:320 (measured by a two-step Spike proteindirected ELISA). CP (9 to 13 ml/kg from donors with S-RBD IgG titer of Ն1:640) was associated with a negative SARS-CoV-2 PCR test at 72 h in 87.2% of the CP group versus 37.5% of the BSC group, but clinical improvement at 28 days was statistically different only in patients with severe, but not in life-threatening, disease (104) . Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 abstract: Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far. url: https://www.ncbi.nlm.nih.gov/pubmed/32792417/ doi: 10.1128/cmr.00072-20 id: cord-271764-um001ffd author: Garraud, Olivier title: Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials? date: 2020-06-27 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://www.sciencedirect.com/science/article/pii/S1473050220301634?v=s5 doi: 10.1016/j.transci.2020.102858 id: cord-304616-k92fa15l author: Izes, Aaron M. title: Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats date: 2020-08-05 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The antimalarial agent mefloquine is currently being investigated for its potential to inhibit feline coronavirus and feline calicivirus infections. A simple, high pressure liquid chromatography assay was developed to detect mefloquine plasma concentrations in feline plasma. The assay’s lower limit of quantification was 250 ng/mL. The mean ± standard deviation intra- and inter-day precision expressed as coefficients of variation were 6.83 ± 1.75 and 5.33 ± 1.37%, respectively, whereas intra- and inter-day accuracy expressed as a percentage of the bias were 11.40 ± 3.73 and 10.59 ± 3.88%, respectively. Accordingly, this validated assay should prove valuable for future in vivo clinical trials of mefloquine as an antiviral agent against feline coronavirus and feline calicivirus. However, the proportion of mefloquine binding to feline plasma proteins has not been reported. The proportion of drug bound to plasma protein binding is an important concept when developing drug dosing regimens. As cats with feline infectious peritonitis (FIP) demonstrate altered concentrations of plasma proteins, the proportion of mefloquine binding to plasma proteins in both clinically normal cats and FIP-affected cats was also investigated. An in vitro method using rapid equilibrium dialysis demonstrated that mefloquine was highly plasma protein bound in both populations (on average > 99%). url: https://doi.org/10.1371/journal.pone.0236754 doi: 10.1371/journal.pone.0236754 id: cord-322714-s0wge7o4 author: Joyner, Michael J. title: Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients date: 2020-07-19 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Abstract Objective To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized COVID-19 patients, having previously demonstrated safety in 5,000 hospitalized patients. Patients and Methods From April 3 to June 2, 2020, the US FDA Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma. Results The incidence of all serious adverse events was low; these included transfusion reactions (n=89; <1%), thromboembolic or thrombotic events (n=87; <1%), and cardiac events (n=680, ∼3%). Notably, the vast majority of the thromboembolic or thrombotic events (n=55) and cardiac events (n=562) were judged to be unrelated to the plasma transfusion per se. The seven-day mortality rate was 8.6% (8.2%, 9.0%), and was higher among more critically-ill patients relative to less ill counterparts, including patients admitted to the intensive care unit vs. not admitted (10.5% vs. 6.0%), mechanically ventilated vs. not ventilated (12.1% vs. 6.2%), and with septic shock or multiple organ dysfunction/failure vs. those without dysfunction/failure (14.0% vs. 7.6%). Conclusion These updated data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality. url: https://www.sciencedirect.com/science/article/pii/S0025619620306510?v=s5 doi: 10.1016/j.mayocp.2020.06.028 id: cord-305130-vz72ldbo author: Keil, Shawn D. title: Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment date: 2020-05-14 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: BACKGROUND AND OBJECTIVE: Severe acute respiratory distress syndrome coronavirus‐2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19), is a member of the coronavirus family. Coronavirus infections in humans are typically associated with respiratory illnesses; however, viral RNA has been isolated in serum from infected patients. Coronaviruses have been identified as a potential low‐risk threat to blood safety. The Mirasol Pathogen Reduction Technology (PRT) System utilizes riboflavin and ultraviolet (UV) light to render blood‐borne pathogens noninfectious, while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against the pandemic virus SARS‐CoV‐2 when tested in both plasma and platelets units. MATERIALS AND METHODS: Stock SARS‐CoV‐2 was grown in Vero cells and inoculated into either plasma or platelet units. Those units were then treated with riboflavin and UV light. The infectious titres of SARS‐CoV‐2 were determined by plaque assay using Vero cells. A total of five (n = 5) plasma and three (n = 3) platelet products were evaluated in this study. RESULTS: In both experiments, the measured titre of SARS‐CoV‐2 was below the limit of detection following treatment with riboflavin and UV light. The mean log reductions in the viral titres were ≥3·40 and ≥4·53 for the plasma units and platelet units, respectively. CONCLUSION: Riboflavin and UV light effectively reduced the titre of SARS‐CoV‐2 in both plasma and platelet products to below the limit of detection in tissue culture. The data suggest that the process would be effective in reducing the theoretical risk of transfusion transmitted SARS‐CoV‐2. url: https://doi.org/10.1111/vox.12937 doi: 10.1111/vox.12937 id: cord-294585-dl5v9p50 author: Klein, H. G. title: Pathogen‐reduction methods: advantages and limits date: 2009-02-13 words: 4519.0 sentences: 216.0 pages: flesch: 40.0 cache: ./cache/cord-294585-dl5v9p50.txt txt: ./txt/cord-294585-dl5v9p50.txt summary: However, because blood contains numerous labile proteins and fragile cells, and because there is a wide array of potentially infectious agents, no single method of pathogen-inactivation will likely preserve all blood components, yet effectively remove all viruses, bacteria, spores, protozoa and prions. Riboflavin/ultraviolet light treatment has been evaluated in preclinical studies and found to result in reduction of infectivity by many pathogens including west Nile virus, intracellular HIV, bacteria and protozoa. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients abstract: Pathogen‐reduction (inactivation) provides a proactive approach to reducing transfusion‐transmitted infection. Pathogen‐reduction technologies have been successfully implemented by plasma fractionators resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US‐licensed plasma derivatives since 1987. Fractionation technologies cannot be used to treat cellular blood components. Although blood donor screening, deferral and disease testing have drastically reduced the incidence of transfusion‐transmitted diseases, the threat of new or re‐emerging pathogens remains. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection. The ultimate goal of pathogen‐inactivation is to reduce transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. The acceptable technology must not introduce toxicities into the blood supply nor result in neoantigen formation and subsequent antibody production. Several promising pathogen‐inactivation technologies are being developed and tested, and others are currently in use, but all of them have limits. Pathogen‐reduction promises an additional ‘layer of protection’ from infectious agents and has the potential to impact the safety of blood transfusions worldwide. url: https://www.ncbi.nlm.nih.gov/pubmed/32328162/ doi: 10.1111/j.1751-2824.2009.01224.x id: cord-284582-xwedgllw author: Korabecna, M. title: Cell-free DNA in plasma as an essential immune system regulator date: 2020-10-15 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The cell-free DNA (cfDNA) is always present in plasma, and it is biomarker of growing interest in prenatal diagnostics as well as in oncology and transplantology for therapy efficiency monitoring. But does this cfDNA have a physiological role? Here we show that cfDNA presence and clearance in plasma of healthy individuals plays an indispensable role in immune system regulation. We exposed THP1 cells to healthy individuals’ plasma with (NP) and without (TP) cfDNA. In cells treated with NP, we found elevated expression of genes whose products maintain immune system homeostasis. Exposure of cells to TP triggered an innate immune response (IIR), documented particularly by elevated expression of pro-inflammatory interleukin 8. The results of mass spectrometry showed a higher abundance of proteins associated with IIR activation due to the regulation of complement cascade in cells cultivated with TP. These expression profiles provide evidence that the presence of cfDNA and its clearance in plasma of healthy individuals regulate fundamental mechanisms of the inflammation process and tissue homeostasis. The detailed understanding how neutrophil extracellular traps and their naturally occurring degradation products affect the performance of immune system is of crucial interest for future medical applications. url: https://doi.org/10.1038/s41598-020-74288-2 doi: 10.1038/s41598-020-74288-2 id: cord-335316-x2t5h5gu author: Madariaga, M. L. L. title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial date: 2020-06-23 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Background: Convalescent plasma therapy for COVID-19 relies on the transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. Methods: Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19. Results: Mean symptom duration of plasma donors was 11.9 and 7.8% (8/103) had been hospitalized. Antibody titers ranged from 0 to 1:3,892 (anti-receptor binding domain (RBD)) and 0 to 1:3,289 (anti-spike). Multivariable analysis demonstrated that higher anti-RBD and anti-spike titer were associated with increased age, hospitalization for COVID-19, fever, and absence of myalgia (all p<0.05). Fatigue was significantly associated with anti-RBD (p=0.03) but not anti-spike antibody titer (p=0.11). In pairwise comparison among ABO blood types, AB donors had higher anti-RBD titer than O negative donors (p=0.048) and higher anti-spike titer than O negative (p=0.015) or O positive (p=0.037) donors. Eight of the ten recipients were discharged, one remains on ECMO and one died on ECMO. No toxicity was associated with plasma transfusion. After excluding two ECMO patients and adjusting for donor antibody titer, recipient anti-RBD antibody titer increased on average 31% per day during the first three days post-transfusion (p=0.01) and anti-spike antibody titer by 40.3% (p=0.02). Conclusion: Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titer to COVID-19. Despite variability in donor titer, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion among COVID-19 patients is needed to determine the clinical efficacy of this therapy. url: http://medrxiv.org/cgi/content/short/2020.06.21.20132944v1?rss=1 doi: 10.1101/2020.06.21.20132944 id: cord-277811-j58qvyum author: Mehrani, Hossein title: Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis date: 2011-01-07 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: INTRODUCTION: Sulfur mustard "bis (2-chlroethyl) sulphide" (SM) is a chemical warfare agent that remains a threat to human health. The aim of this study was to identify protein expression signature or biomarkers that reflect chronic lung damages induced by SM exposure. METHODS: Prior to analysis, plasma was fractionated using ethanol precipitation. Using two dimensional SDS-PAGE; fractionated protein profiles of 20 healthy and 20 exposed patients with lung diseases were established. Selected protein spots were successfully identified with MALDI TOF MS/MS. RESULTS: The results show that α1 haptoglobin isoforms were detected in plasma of the all lung disease patients but none of the healthy controls. Amyloid A1 isoforms was also detected in plasma of the lung disease patients but none of the healthy controls. Moreover, low molecular weight proteins were enriched in ethanol supernatant compared to ethanol precipitate. CONCLUSION: Our present results and previous studies suggest that ongoing tissue remodeling is involved in SM exposed lung damage patients. These finding might improve patient care and suitable therapies. url: https://www.ncbi.nlm.nih.gov/pubmed/21906349/ doi: 10.1186/1559-0275-8-2 id: cord-280221-s6oxq772 author: Montelongo-Jauregui, Daniel title: Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease date: 2020-08-12 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32785259/ doi: 10.1371/journal.ppat.1008735 id: cord-270908-9snyt2n1 author: PERSSON, C. G. A. title: Airway permeability date: 2006-04-27 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/8564718/ doi: 10.1111/j.1365-2222.1995.tb00022.x id: cord-326176-n0xo3e53 author: Patel, Reema T. title: Multiple myeloma in 16 cats: a retrospective study date: 2008-03-05 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Background: There is limited published information regarding feline multiple myeloma. Diagnostic criteria are derived from canine studies and to our knowledge, have not been critically reviewed for cats. Objective: To evaluate the clinical and laboratory findings in cats with multiple myeloma and appraise diagnostic criteria. Methods: Retrospective evaluation of medical records was performed. Inclusion required an antemortem diagnosis of multiple myeloma using 2 of 4 criteria: 1) ≥20% plasma cells in the bone marrow, or ≥10% if atypical plasma cells; 2) paraproteinemia; 3) radiographically‐evident osteolysis; 4) light chain proteinuria. Alternatively, a postmortem diagnosis was based on the findings of multiple plasma cell neoplasms, with marrow involvement. Results: Sixteen cats were diagnosed with multiple myeloma between 1996 and 2004, with a median age of 14.0 years; 9 of 16 (56%) were castrated males, and 7 of 16 (44%) were spayed females. Laboratory abnormalities included hyperglobulinemia (14/16, 87.5%), with 11/14 (78.5%) monoclonal and 3/14 (21.4%) biclonal gammopathies; hypoalbuminemia (4/16, 25%); light chain proteinuria, (4/9, 44.4%); hypocholesterolemia (11/16, 68.7%); hypercalcemia, (3/15, 20%); nonregenerative anemia, (11/16, 68.7%); regenerative anemia, (1/16, 6.2%); neutropenia (5/15, 33.3%); thrombocytopenia (8/16, 50%); and marrow plasmacytosis (14/15, 93.3%). Plasma cells were markedly immature, atypical, or both in 10 of 12 (83.3%) cats. Focal or multifocal osteolysis was noted in 6 of 12 (50%) cats for which radiographs were available for review; generalized osteopenia was found in 1 (8.3%) cat. Noncutaneous, extramedullary tumors were found in all cats assessed, 7/7 (100%), including spleen (6), liver (3), and lymph nodes (4). The disease in 1 of 2 cats with cutaneous tumors progressed to plasmacytic leukemia. Conclusions: Common findings in feline multiple myeloma include atypical plasma cell morphology, hypocholesterolemia, anemia, bone lesions, and multi‐organ involvement. Based on the results of this study, we advocate modifying diagnostic criteria in cats to include consideration of plasma cell morphology and visceral organ infiltration. url: https://www.ncbi.nlm.nih.gov/pubmed/16270258/ doi: 10.1111/j.1939-165x.2005.tb00059.x id: cord-006192-bqwchhwk author: Persson, Carl G. A. title: Plasma exudation and asthma date: 1988 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Several pieces of evidence support the view that exudation of plasma into the airway wall and into the airway lumen occurs in asthma. Vascular leakage of plasma results from inflammatory mediator-induced separation of endothelial cells in postcapillary venules belonging to the tracheobronchial circulation. Whereas proposed mediators of asthma induce reversible leakage, several antiasthma drugs exhibit antileakage effects in animals and humans. Potential consequences of plasma exudation are many. Mucosal/submucosal edema might contribute to airway hyperresponsiveness. Plasma exudate in the airway lumen in asthma may contribute to sloughing of epithelium, impairment of mucociliary transport, narrowing of small airways, and mucus plug formation. Exuded plasma may cause airway inflammation and constriction because of its content of powerful mediators, and chemoattractant factors and plasma proteins may condition the inflammatory cells abundant in asthmatic airways to release mediators in response to stimuli that otherwise would be innocuous to the cells. It is concluded that inflammatory stimulus-induced increase in macromolecular permeability of the tracheobronchial microvasculature and mucosa may be a significant pathogenetic mechanism in asthma and that the postcapillary venular endothelium and airway epithelium that regulate leakage of plasma are important effector cells in this disease. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100194/ doi: 10.1007/bf02714025 id: cord-352985-5ccrkfsa author: Putter, Jeffrey S. title: An Update on COVID-19 Infection Control Measures, Plasma-Based Therapeutics, Corticosteroid Pharmacotherapy and Vaccine Research date: 2020-09-04 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: This communication provides a compilation on aspects of COVID-19 infection control measures, describes the potential role of therapeutic plasma exchange to reduce fatality rates, addresses precautions concerning dexamethasone pharmacotherapy and updates the current status on the availability of vaccines. As part of passive immunotherapy, it focuses on various blood derivatives. These include coronavirus neutralising antibodies extracted from different sources to be administered as a pure hyper concentrate intramuscularly or for upgrading and standardising the specific potency of high affinity antibodies. These processes are intended to compose standardised pooled bioproducts of corona convalescent plasma/cryosupernatant that are pathogen inactivated for additional safety by well-established UV technologies. For the best practice of optimising plasma exchange, hyper concentrate NAb should be added to the cryosupernatant, which contains some of the active principles of corona convalescent plasma. The cryosupernatant apart from the high molecular weight viscous part of cold insoluble proteins that are removed, is equivalent to CCP, but makes it safer for general application. Such a bioproduct is often used routinely for substitution therapy of thrombotic thrombocytopenic purpura. Alternative resources of large-scale specific coronavirus antibodies warrant further exploration such as cadaveric donations. The early uses of therapeutic plasma exchange and low molecular weight heparin, for any clinical trial in development is warranted, in order to interdict the intense inflammatory/kinin driven cascade. Because coronavirus positive patients are highly prone to thrombosis, thromboprophylaxis is necessary, even some time after recovery guided by the laboratory data. url: https://www.ncbi.nlm.nih.gov/pubmed/32948465/ doi: 10.1016/j.transci.2020.102934 id: cord-018845-r88bhiac author: Sachs, U. J. H. title: Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten date: 2010-11-21 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Blutspender leisten einen wertvollen Dienst für die Gemeinschaft: Die ständige Verfügbarkeit von Blutkomponenten ist zur unverzichtbaren Voraussetzung für viele Bereiche der Medizin geworden. Nicht nur die Gewinnung und Aufarbeitung von Blut und Blutbestandteilen zur Sicherstellung einer qualitativ wie quantitativ guten Versorgung, sondern auch die kompetente Betreuung der Spender ist eine der großen Aufgaben der Transfusionsmedizin. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123830/ doi: 10.1007/978-3-642-12765-6_16 id: cord-282252-07uzz649 author: Sahu, Kamal Kant title: Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19 date: 2020-05-21 words: 1366.0 sentences: 94.0 pages: flesch: 55.0 cache: ./cache/cord-282252-07uzz649.txt txt: ./txt/cord-282252-07uzz649.txt summary: The basic concept for use of convalescent plasma in COVID-19 is as a delivery system for viral neutralizing antibodies, that is to confer passive immunity. Considering the aforementioned limitations and the potential risks, appropriate triage systems should be utilized; hence, plasma therapy use is currently restricted only to critically ill patients. The FDA recommends two clinical indications for the current usage of convalescent plasma therapy in COVID-19 patients(12) Scenario A (Severe disease) which is defined as one or more of the following: On April 3, 2020, the FDA cleared the path for the use of this potential lifesaving therapy under any of the following three routes[1] enrollment in a clinical trial, [2] via the national expanded access treatment protocol, and [3] under a single patient emergency investigational new drug application (eIND). Lacking a vaccine and with limited antiviral options against SARS-CoV-2, this is an ideal time to try convalescent plasma therapy in COVID-19 patients. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients abstract: As of May 19, 2020, there are in total 4,986,200 laboratory‐confirmed Coronavirus disease‐2019 (COVID‐19) cases. 2% (45,425) out of 2,657,390 active COVID‐19 cases are critically ill and might be requiring intensive care support.(1,2) Unfortunately, even after six months since its first detection, we still do not have any definitive treatment options for COVID‐19 pneumonia. This article is protected by copyright. All rights reserved. url: https://doi.org/10.1002/jmv.26047 doi: 10.1002/jmv.26047 id: cord-018142-xt71w4nr author: Samy Modeliar, S. title: Thrombotic Microangiopathy Syndrome in the ICU date: 2006 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Major studies designed to improve our understanding of the pathophysiology of TMA have been conducted over recent years. This improved knowledge opens up new perspectives for more targeted treatment. However, until these innovative treatments become available, early diagnosis of these diseases is essential in order to rapidly initiate specific treatment, as the interval between diagnosis and initiation of plasma exchange is a decisive element in the prognosis of TTP. Treatment must not be stopped too early or too rapidly and must take into account the various associated factors, especially the presence of infection. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122943/ doi: 10.1007/3-540-33396-7_20 id: cord-336177-p7b7yw28 author: Selvi, Valeria title: Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives date: 2020-09-22 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: On March 11(th), 2020, the World Health Organization declared COVID-19 infection as a pandemic. Since it is a novel virus, there are basically no proven drugs or therapies; although many laboratories in different countries are working to develop a vaccine, it will take time to make it available. Passive immunization is the therapy born from the intuition of Behring and Kisato in the late 19(th) century. It was widely used for the treatment of bacterial infections until the discovery of antibiotics, as well as during the viral pandemics of the 20(th) century and of the beginning of the 21(st); it still has clinical applications (e.g., tetanus prevention). This paper summarizes the basic principles of passive immunization, with particular reference to convalescent plasma. The literature concerning its use during past epidemics and the results of the first clinical studies concerning its use during the current pandemic are discussed too. A large section is dedicated to the analysis of the possible, although rare, side effects. Recently, in 2017, the WHO Blood Regulators Network (BRN) published a position paper, recommending convalescent plasma as the first-choice treatment to be tested in the absence of authorized drugs; however, this strategy has not been followed. In the current epidemic, the principle of passive immunization through convalescent plasma has been applied in several circumstances and particularly in patients with serious complications. The first reported results are encouraging and confirm the effectiveness of plasma therapy and its safety. Also, the FDA has proposed plasma treatment in order to face the increasingly complex situation and manage patients with serious or immediately life-threatening COVID-19 disease. Several studies and clinical programs are still ongoing. url: https://doi.org/10.1155/2020/2606058 doi: 10.1155/2020/2606058 id: cord-329228-yjvw2ee1 author: Shikata, N. title: Multi-layered network structure of amino acid (AA) metabolism characterized by each essential AA-deficient condition date: 2006-10-13 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The concentrations of free amino acids in plasma change coordinately and their profiles show distinctive features in various physiological conditions; however, their behavior can not always be explained by the conventional flow-based metabolic pathway network. In this study, we have revealed the interrelatedness of the plasma amino acids and inferred their network structure with threshold-test analysis and multilevel-digraph analysis methods using the plasma samples of rats which are fed diet deficient in single essential amino acid. In the inferred network, we could draw some interesting interrelations between plasma amino acids as follows: 1) Lysine is located at the top control level and has effects on almost all of the other plasma amino acids. 2) Threonine plays a role in a hub in the network, which has direct links to the most number of other amino acids. 3) Threonine and methionine are interrelated to each other and form a loop structure. url: https://www.ncbi.nlm.nih.gov/pubmed/17031477/ doi: 10.1007/s00726-006-0412-0 id: cord-294684-wfsdjs1f author: Vesnaver, Elisabeth title: Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study date: 2020-11-02 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: BACKGROUND: Blood donation policy in Canada for gay, bisexual and other men who have had sex with men (gbMSM) has changed progressively in the last decade from indefinite deferral to 3-month deferral from last male-to-male sex. Driven by safety data and overseen by the national regulator, more inclusive policies continue to redress the disparity in donation for gbMSM. At the same time, the need for source plasma to prepare fractionated blood products is growing worldwide. The collection and processing of source plasma ensures greater safety compared to whole blood donation with respect to transfusion-transmitted infection. This greater safety offers an opportunity to evolve policies for gbMSM from time-based to behaviour-based deferral using revised eligibility criteria. However, changing policies does not in itself necessarily guarantee that gbMSM will donate or that staff in donor clinics are ready to support them to do so. In anticipation of a move to behaviour-based donation screening for gbMSM in Canada, we aim to assess the acceptability of and perceived barriers and enablers to source plasma donation using revised screening criteria for gbMSM among key stakeholders to inform policy implementation strategies. METHODS: This mixed-methods feasibility study will involve gbMSM and donor centre staff to understand modifiable barriers to implementing more inclusive eligibility criteria. Key informant interviews and surveys will be rooted in the Theoretical Domains Framework to identify modifiable factors associated with source plasma donation motives in gbMSM and training needs in donation centre staff. We will use an integrated knowledge translation approach involving a partnership between researchers, the national blood operator and gbMSM, situating knowledge users as key research team members to ensure their perspectives inform all aspects of the research. DISCUSSION: Our integrated knowledge translation approach will provide a more comprehensive and collaborative understanding of blood operator and gbMSM needs while accelerating the implementation of study findings. Given the historical backdrop of the decades of exclusion of sexually active gbMSM from blood donation, this study has the potential not only to inform a process and policy for gbMSM to donate source plasma, a blood product, but also offers opportunities for new relationships between these knowledge users. url: https://www.ncbi.nlm.nih.gov/pubmed/33138828/ doi: 10.1186/s12961-020-00643-4 id: cord-323656-bzefn894 author: Yoo, Jin-Hong title: Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying date: 2020-04-06 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32281318/ doi: 10.3346/jkms.2020.35.e150 id: cord-018492-d34tyar7 author: Zaza, Mouayyad title: Dried Plasma date: 2019-05-06 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: Dried plasma provides an alternative for early plasma transfusion in the resuscitation of hemorrhagic shock in environments where fresh frozen plasma is not immediately available. It is produced by freeze-drying or spray-drying liquid or thawed plasma. It is shelf-stable for prolonged periods, can be stored at room temperature, and is easy to transport, reconstitute, and administer. It was widely used in WWII but fell out of favor due to the risk of infectious disease transmission. The German and French experiences with lyophilized plasma are the most extensive and show a good track record of efficacy and safety. Recent studies show many beneficial effects of dried plasma in the treatment of shock in large animal models. Currently, no FDA-licensed product is available in the USA, but several are under development. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123378/ doi: 10.1007/978-3-030-20820-2_8 id: cord-284208-8fsqgkw5 author: Zolla, Lello title: Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins date: 2008-11-07 words: nan sentences: nan pages: flesch: nan cache: txt: summary: abstract: The most abundant proteins in serum, such as albumin and IgG, act as molecular sponges that bind and transport low molecular weight proteins/peptides and drugs. In the near future, pharmacoproteomics, the use of proteomic technologies in the field of drug discovery and development, and interactomics, the branch of proteomics which is concerned with identifying interactions between proteins, will allow researchers to (i) know the specific protein changes that occur in biological compartments in response to drug administration; (ii) design small novel therapeutic molecules that can have extended half-lives if carried by plasma protein in the blood stream. Advances in these fields will open new avenues of tailor-made molecular therapy, reducing present limitations on treatment arising from toxicity and inefficiency. In this short review we report and discuss the most recent developments arising from the use of proteomic tools in blood plasma protein research, looking at the identification of proteins found in plasma as well as their interactions with small molecules such as drugs, peptides, organic chemicals and metals. We believe this research demonstrates that proteomic technologies, and in particular pharmacoproteomics, interactomics and post-translational modification analysis, could be instrumental in the design of new tailor-made drugs leading to substantial improvements in molecular therapy. url: https://doi.org/10.1016/j.drudis.2008.09.013 doi: 10.1016/j.drudis.2008.09.013 id: cord-006860-a3b8hyyr author: nan title: 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) date: 1996 words: 90660.0 sentences: 5152.0 pages: flesch: 50.0 cache: ./cache/cord-006860-a3b8hyyr.txt txt: ./txt/cord-006860-a3b8hyyr.txt summary: Dept of Pediatrics, University Hospitals Kiel and Mtinster, Germany Resistance to activated protein C (APCR), in the majority of cases associated with the Arg 506 Gin point mutation in the factor V gene is present in more than 50 % of patients < 60 years of age with unexplained thrombophilia. The regular APC resistance test is not applicable to plasma from Orally anticoagulated (OAC) or heparinized patients due to decreased levels of vitamin K-dependent clotting factors and to thrombin inhibition by antithrombin, respectively. On admission an extensive coagulation screen yielded the following results (n/normal, t/elevated, I/reduced, +/positive, -/negative): PT t, aPTT t, Tr n, factor II, V, VIII n, factor VII, IX, XI, XII /,, fibrinogan t, ATIII n, protein C, S *, activated protein C sensitivity ratio 1.92 ($), FV-Leidenmutation PCR -, fibrinolytic system n, TAT t, Ft÷2 t, lupus anticoagulant +, heparin induced platelet antibodies +; no diagnosis of a specific autoimmuna disorder could be made. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103196/ doi: 10.1007/bf00641048 id: cord-031907-ilhr3iu5 author: nan title: ISEV2020 Abstract Book date: 2020-07-15 words: 200999.0 sentences: 11528.0 pages: flesch: 44.0 cache: ./cache/cord-031907-ilhr3iu5.txt txt: ./txt/cord-031907-ilhr3iu5.txt summary: L.M., and the National Institutes of Health (R35GM119623) to T.R.G. The addition of a size exclusion chromatography step to various urinary extracellular vesicle concentrating methods reveals differences in the small RNA profile Introduction: Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases, however non-vesicular RNA (e.g. associated with proteins) is also present within urine. We then evaluated efficiency of heart targeting for eAAV9 or eAAV6 and standard AAV9 or AAV6 encoding for EGFP, mCherry or firefly luciferase in different human cell lines in vitro, in black mouse and in passive immunity nude mouse model in vivo using flow cytometry, confocal microscopy, Langendorff perfusion system and Methods: HLHS patients (n = 3) after Glenn procedure and swine (n = 3) after PAB were given RV injections of allogeneic/xenogeneic MSCs. Donor-specific, HLA-I+, exosomes were isolated from plasma. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480431/ doi: 10.1080/20013078.2020.1784511 ==== make-pages.sh questions [ERIC WAS HERE] ==== make-pages.sh search /data-disk/reader-compute/reader-cord/bin/make-pages.sh: line 77: /data-disk/reader-compute/reader-cord/tmp/search.htm: No such file or directory Traceback (most recent call last): File "/data-disk/reader-compute/reader-cord/bin/tsv2htm-search.py", line 51, in with open( TEMPLATE, 'r' ) as handle : htm = handle.read() FileNotFoundError: [Errno 2] No such file or directory: '/data-disk/reader-compute/reader-cord/tmp/search.htm' ==== make-pages.sh topic modeling corpus Zipping study carrel